GLP-1s for 6-Year-Olds; Trial Shows BMI Reduction and Slower Height Growth In Young Children
Updated
A Novo Nordisk-funded trial published this week in the New England Journal of Medicine and presented at ObesityWeek is being promoted as evidence that weekly semaglutide (Wegovy) can reduce BMI in children ages 6 to under 12 with obesity. The results show a 13.5% drop in BMI at 68 weeks on the drug versus a 2.7% rise on placebo. 38% of the treated children fell below the obesity threshold at week 68 and 33% at week 104. The same data also show those children grew more slowly in height. The lifestyle counseling both groups received was not defined or enforced. Long-term effects on final adult height, bone, and development remain unknown. Critics say the study is being used to expand a lucrative market rather than address the root causes of childhood obesity.
The FDA has currently only approved GLP-1s for weight loss for children 12 and up, but there have been over 20,000 children aged 8-11 who have been prescribed GLP-1 drugs off-label for weight loss. The latest CDC data says about 20% of youth aged 2-19 have obesity. A research brief published in Pediatrics on September 4 reveals that there has been a 310-fold increase in the percentage of children aged 8-11 with obesity and without diabetes who were prescribed GLP-1s for weight loss between 2019 and 2026. It was 0.03% in 2019 and increased to 9.3% in 2026.
Novo Nordisk is moving forward with clinical trials in an attempt to get the drugs approved for obese children as young as 6.
The STEP Young trial randomized 167 children with a mean age of about 10 years old, with two-thirds of the children receiving semaglutide once per week and one-third serving as the placebo group. More than 85% of the participants had severe class II or class III obesity. Both cohorts were given lifestyle counseling to reduce calorie intake and increase physical activity, but the specific details of this counseling were not disclosed in the published study.
The trial endpoint was at 68 weeks, with a 13.5% drop in BMI for the semaglutide group and a 2.7% increase for the placebo group. The researchers also tracked the height and the amount of growth for each group. The placebo group grew 37% more than the semaglutide group after 68 weeks and 38% more after 104 weeks. The researchers suggest the reduction in BMI could be causing the slowed linear growth for the semaglutide group because obesity is linked to accelerated linear growth before puberty. There are no existing long-term data for heights in adulthood after receiving semaglutide as a child.
Novo Nordisk issued a press release celebrating the BMI reduction associated with the semaglutide group, but did not mention the slowed height growth or the limitations of the study. 40% of the placebo group dropped out by week 104, and the researchers did not screen participants for eating disorders.
Ania M. Jastreboff, MD, PhD, Professor of Medicine and Pediatrics and Director of the Yale Obesity Research Center, is listed as the lead author on the study. She has over three dozen disclosures, including consulting work for Novo Nordisk and Eli Lilly, the two largest GLP-1 manufacturers. Jastreboff has been paid over $548,000 to conduct research for Eli Lilly and over $90,000 to do research for Novo Nordisk, most of which has occurred since 2024. Jastreboff has also received over $54,000 in general payments from Eli Lilly and $33,000 from Novo Nordisk, according to open payments data.
Jastreboff is quoted in Novo Nordisk’s press release stating, “Childhood obesity is particularly concerning due to both immediate and enduring impacts on health, including a strong predilection to adult obesity and increased risk for the early emergence of obesity-related complications.”
As with the side effects for adults who use GLP-1s, the most common side effects were gastrointestinal. 70% of the semaglutide group experienced vomiting compared to 29% of the control group, and 62% experienced diarrhea compared to 35% in the control group, and 58% experienced nausea compared to 24% in the control group.
U.S. children and adolescents get roughly two-thirds of their daily calories from ultra-processed foods (UPF). 65% of children are getting 10% or more of their daily calories from sugar. Both UPFs and sugar intake are associated with childhood obesity. Children with obesity get an average of 18.5% of their daily calories from added sugars.
Multiple randomized controlled trials and systematic reviews show that dietary changes can reduce BMI for children with obesity. A 2024 Brazilian randomized controlled trial of children ages 7-12 with obesity reduced the amount of UPFs and created individualized energy-restricted meal plans. The intervention group decreased their BMI over six months, while the control group with only education assistance gained BMI during the study period.
A 2023 systematic review and meta-analysis found “a broad array of diet types were effective at reducing BMI in children with obesity.” Diets with some form of caloric restriction were effective, while those that focused on healthy eating habits alone were ineffective.
The Novo Nordisk trial compared the semaglutide group with a control group that received counseling rather than a specific dietary plan. The press release states, “The overall safety and tolerability of semaglutide were consistent with those seen in adults and adolescents trials with semaglutide.”
The FDA is now requiring warnings on GLP-1 drugs for non-arteritic anterior ischemic optic neuropathy (NAION), a type of sudden vision loss and blindness. This is added to the current list of warnings for Wegovy, which currently includes “risk of thyroid C-cell tumors (including medullary thyroid carcinoma), personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), serious hypersensitivity reactions (anaphylaxis, angioedema), acute pancreatitis (including fatal and non-fatal hemorrhagic or necrotizing pancreatitis), acute gallbladder disease (cholelithiasis, cholecystitis), hypoglycemia, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, diabetic retinopathy complications, increased heart rate, pulmonary aspiration during general anesthesia or deep sedation, severe gastroparesis, risk of fetal harm in pregnancy.”
There are currently over 4,000 pending lawsuits against GLP-1 manufacturers related to gastroparesis and gastrointestinal damage and over 270 pending NAION cases.